Genmab — Maj 2018

[peter12]

Glædeligt at aqr ikke snyder og er blevet i aktien Thumbsup fra mig

[JKY_VH]

Plimsoller, Novod nævner et par andre muligheder: forsøg i solide genoptages efter data granskning, Car-T flopper i MM og take over.

[Bella1]

har lige knaldet (sparegrisen forstås) og købt yderligere en sjat, - lidt billigere end 12.49

[Plimsoller]

Tak JKY_VH

[Tyndeejner]

Tillykke @Bella1, held og lykke med investeringen. Jeg har dog hørt på vandrørene, at OHW overvejer at nedjusterer forventningerne, måske vi snart får et nyt target på bunden fra ham. @OHW, kun lidt drillerier her fra, 970 bliver luk i dag, og så fik du ret

[JKY_VH]

så skal den da vist snart i omdrejninger Tyndeejner:-)

[Repsac]

Det er overskrifter som denne, der får menig mand til at blive meget nervøs...https://seekingalpha.com/news/3359952

[E_L]

the ph2 "Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens" started recruiting - https://clinicaltrials.gov/ct2/history/NCT03412565?A=5&B=6&C=merged

[Soeborg]

Repsac,sandheden er altid ilde hørt

[gentogen]

Måske Genmab skulle udsende lidt meddelelser med denne slags indhold: "Daratumumab plus KRd is highly effective, with a 100% ORR,
including 91% of patients with ≥VGPR and 57% of patients
with ≥CR" (en gammel, men ganske hyggelig 'nyhed' fra december). http://files.shareholder.com/downloads/AMDA-KPIBN/6109548743x0x966333/8815E418-E24F-48D8-9137-B552120120C5/Chari_MMY1001_D-KRd.pdf

[JKY_VH]

præcis gentogen

[GeorgeBest]

Den bliver præsenteret på ASCO. Så kommer updates derefter

[lahn1]

Vi lukker i 953,20 men hellere flad en nedtur

[GeorgeBest]

Genmab to Present at the Goldman Sachs 39th Annual Global Healthcare Conference http://ir.genmab.com/releasedetail.cfm?ReleaseID=1068666

[Tyndeejner]

Min PF er blod rød i dag, så hvis GEN bare er i et lille plus, så er jeg særdeles tilfreds.

[Solsen]

https://finanswatch.dk/Finansnyt/Pengeinstitutter/article10642887.ece?utm_source=Feed&utm_medium=latest Farlige Frank stopper pga Mifid II

[lahn1]

Tyndeejner: Ja det er en rød dag med GEN i plus, men sjovt nok sidder jeg ikke og smiler. Lad os teste 970 imorgen igen og håbe den holder. Lidt flot at GEN trods alt er i plus idag.

[E_L]

http://www.epvantage.com/Universal/View.aspx?type=Story&id=791149&isEPVantage=yes

[Helge_LarsenPI-redaktør]

"Still, even without this combination setting Darzalex is expected to be hugely successful in multiple myeloma – the indication accounts for the entire $6bn of EvaluatePharma's consensus forecast in 2024. And Genmab has more important readouts coming up, with the first-line Maia and Cassiopeia trials due to report this year.

Knock-out results will help rebuild confidence in the company, but any hint of disappointment – or any more safety worries – would be another big blow to sentiment".

[Helge_LarsenPI-redaktør]

"A spokesperson for Genmab told EP Vantage that the company could not give more details as it could not speak for Johnson & Johnson, its partner on Darzalex. J&J is developing and commercialising the drug under an exclusive licensing deal signed in 2012 – the company had not responded to a request for more information on the remaining combo trials at the time of publication".